ArticleEmerging infectious diseases2021
Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 47 citations in OpenAlex.
- Validation of sample pooling for high-throughput RT-qPCR subtyping of avian influenza A(H5).Microbiology spectrum · 2026Article
- Acute SARS-CoV-2 infection.Nature reviews. Disease primers · 2025Review
- Advancements and Applications of Split Technology in CRISPR/Cas12a: Transforming Molecular Diagnostics and Biosensing.Biosensors · 2025Review
- Development of a Diagnostic Microfluidic Chip for SARS-CoV-2 Detection in Saliva and Nasopharyngeal Samples.Viruses · 2024Article
- Development of a simple and highly sensitive virion concentration method to detect SARS-CoV-2 in saliva.Heliyon · 2024Article
- Rapid Nucleic Acid Diagnostic Technology for Pandemic Diseases.Molecules (Basel, Switzerland) · 2024Review
- Pooled RNA-extraction-free testing of saliva for the detection of SARS-CoV-2.Scientific reports · 2023Article
- Using Real-Time PCR Fluorescence Reaction Values to Improve SARS-CoV-2 Virus Detection and Benefit Clinical Decision-Making.Life (Basel, Switzerland) · 2023Article
- A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples.Frontiers in public health · 2023Article
- Saliva-direct approach in the detection of SARS-CoV-2 in the lower-risk population in Colombia.Health science reports · 2023Article
- Accelerating the Laboratory Testing Capacity through Saliva Pooling Prior to Direct RT-qPCR for SARS-CoV-2 Detection.Diagnostics (Basel, Switzerland) · 2022Article
- Saliva-based methods for SARS-CoV-2 testing in low- and middle-income countries.Bulletin of the World Health Organization · 2022Article
- Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity.Clinics in laboratory medicine · 2022Review
- Comparison of Saliva and Midturbinate Swabs for Detection of SARS-CoV-2.Microbiology spectrum · 2022Article
- Pooling saliva samples as an excellent option to increase the surveillance for SARS-CoV-2 when re-opening community settings.PloS one · 2022Article
- Sequencing SARS-CoV-2 genomes from saliva.Virus evolution · 2022Article
- SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan.PloS one · 2022Article
- Article
- Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test.Microbiology spectrum · 2021Article
- Safe and effective pool testing for SARS-CoV-2 detection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2021Article
Corrections and comments
- Update of
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
We analyzed feasibility of pooling saliva samples for severe acute respiratory syndrome coronavirus 2 testing and found that sensitivity decreased according to pool size: 5 samples/pool, 7.4% reduction; 10 samples/pool, 11.1%; and 20 samples/pool, 14.8%. When virus prevalence is >2.6%, pools of 5 require fewer tests; when <0.6%, pools of 20 support screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.